Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs TC Energy Corporation Common Stock (TRP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs TC Energy Corporation Common Stock — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while TC Energy Corporation Common Stock trades at $60.84 (market cap $63.97B). The key difference: TC Energy Corporation Common Stock is far larger — about 12.3× Oruka Therapeutics Inc. Common Stock's market cap, and TC Energy Corporation Common Stock pays a 4.02% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and TC Energy Corporation Common Stock for 6 Days on average.
| ORKA | TRP | |
|---|---|---|
Market Cap | $5.18B | $63.97B |
Volume | 490,798 | 3,039,280 |
Sector | Health | Energy |
52-Week High | $113.08 | $70.91 |
52-Week Low | $26.19 | $49.79 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $4.31B | $108.73B |
Dividend Yield | — | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TRP trades at $61.55, up 1.63% with a bullish technical signal despite mixed moving averages. The company shows solid fundamentals with $15.24B revenue, 22.91% net margin, and consistent EBITDA growth. Recent developments include Coastal GasLink Phase 2 expansion approval and a $400M pipeline divestiture, positioning for long-term natural gas demand growth. Analyst consensus is strongly bullish with a $85 price target representing 38% upside potential.
TRP presents a compelling investment case with strong profitability, strategic growth initiatives, and overwhelming analyst support. Key risks include execution challenges on major projects, interest rate sensitivity, and energy market volatility. The stock's current valuation at 25x P/E appears reasonable given growth prospects and 4.3% dividend yield, though technical indicators suggest near-term consolidation may occur.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About TC Energy Corporation Common Stock
TC Energy operates energy infrastructure, including natural gas pipelines and storage systems. Its assets transport energy across North America.
Read more on TRP →
